JFA
VKTX icon

JNBA Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

JNBA Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,300
Closed -$55.5K – 690
2025
Q1 		$55.5K Buy
+2,300
New +$72.7K 0.01% 270

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

JNBA Financial Advisors's VKTX Position: Q2 2025 in Review

JNBA Financial Advisors sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 2,300 shares — an estimated $55.5K sold.

JNBA Financial Advisors first reported a position in VKTX in Q1 2025 and held it in 1 quarter. The position peaked at $55.5K in Q1 2025. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • JNBA Financial Advisors reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • JNBA Financial Advisors sold 2,300 Viking Therapeutics shares in Q2 2025, an estimated $55.5K.
  • JNBA Financial Advisors first reported a position in Viking Therapeutics in Q1 2025 and held it in 1 quarter.
  • JNBA Financial Advisors's Viking Therapeutics position peaked at $55.5K in Q1 2025.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on JNBA Financial Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.